Abeona Therapeutics ABEOW 深 沪
已收盘 01-09 16:00:00 美东时间
0.0698
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0698
- 总市值 2.11亿
- 52周最高 4.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.021
- 委 比 0.00%
- 总股本 30.28亿
- 历史最高 17.56
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.021
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Abeona Therapeutics announces resignation of board member
Abeona Therapeutics ( ($ABEO) ) just unveiled an update. On June 11, 2026, Abeo...
06-12 20:01
Abeona Therapeutics director Michael Amoroso resigns from board, committee roles
Abeona Therapeutics director Michael Amoroso resigns from board, committee roles Abeona Therapeutics reported the resignation of director Michael Amoroso, effective immediately on June 11, 2026. Amoroso also stepped down from the board’s Nominating and Corporate Governance Committee. The departure w
06-12 19:31
Abeona CFO Joseph Vazzano disposes of 49,338 common shares worth $266,815
Abeona CFO Joseph Vazzano disposes of 49,338 common shares worth $266,815 Abeona Therapeutics CFO Joseph Walter Vazzano sold 49,338 common shares on June 8-9, 2026 at weighted-average prices near USD 5.30-5.43. Holdings fell to 518,437 shares following the transactions. Sales included tax-withholdin
06-10 08:33
Abeona Advances ABO-701 T-Cell Therapy Toward IND
Abeona Therapeutics ( ($ABEO) ) has shared an update. On June 3, 2026, Abeona T...
06-04 20:00
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
05-28 18:25
Abeona Therapeutics Highlights Strong ZEVASKYN Launch Momentum
Abeona Therapeutics Inc (($ABEO)) has held its Q1 earnings call. Read on for th...
05-20 13:21
Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript
On Wednesday, Abeona Therapeutics (NASDAQ:ABEO) discussed first-quarter financi...
05-13 21:51
Abeona Therapeutics posts smaller-than-expected Q1 loss per share
Abeona Therapeutics posts smaller-than-expected Q1 loss per share Overview US biopharma's Q1 net product revenue rose quarter-over-quarter as ZEVASKYN adoption increased Q1 loss per share beat analyst expectations Co has $168.3M in cash, cash equivalents and short-term investments as of March 31, 20
05-13 19:40
Abeona Therapeutics Q1 EPS $(0.30) Beats $(0.35) Estimate, Sales $8.720M Beat $4.572M Estimate
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.35) by 14.29 percent. This is a 25 percent decrease over losses of $(0.24) per share from
05-13 19:35
Abeona Q1 FY26 net loss widens to $17.1 million; revenue rises to $8.7 million
Abeona Q1 FY26 net loss widens to $17.1 million; revenue rises to $8.7 million Abeona Therapeutics posted Q1 2026 revenue of USD 8.7 million, up USD 6.3 million from Q4 2025, as net loss widened to USD 17.1 million, or USD 0.30 per share. Selling, general and administrative expense climbed to USD 19
05-13 19:31
